Auckland University researchers posts that drug they have helped designed has been successful in extending spectacular results in tissue repair during phase 2 clinical trials, and may now offer new hope to patients with chronic wounds as it initiated on the path to enter in the global 'wound-healing' market.
The drug is named as Nexagon and it is applied to wounds that are difficult to heal, especially leg ulcers.
The drug is being designed by CoDa Therapeutics, a Company with dual operations in NZ and the USA that has been financially aided by BioPacificVentures, a New Zealand venture capital group and other international investors.
The drug is on the verge to enter the most critical 'phase three' stage of clinical trials, where its efficacy will be tested against existing means of wound treatment in hundreds of patients.
The Company reveals that in contrast to other treatments in the same category, Nexagon works in a different manner, making use of a 'blocking technology' considered to be significantly good in helping with chronic and slow-to-heal wounds.
Company President and CEO Brad Duft quoted; CoDa's links to New Zealand is witnessed to be "a significant component in the company's success".